Press materials
PRESS RELEASES
Adcendo ApS Announces Phase 1 Clinical Data Showing Compelling Safety & Antitumor Activity with ADCE-D01 in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
30% objective response rate and an 85% disease control rate on every 2-week (Q2W) schedule; all responses ongoing at data cut-off Favorable safety and tolerability profile with very few patients needing dose reduction and no discontinuation for side effects on Q2W...
Adcendo ApS to Present ADCE-D01 Phase 1 Clinical Data in Advanced Soft Tissue Sarcoma in Late-Breaking Oral Presentation at 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Presentation at plenary session on clinical trials will highlight initial clinical data from ongoing ADCElerate1 trial in patients with advanced soft tissue sarcoma Copenhagen, Denmark, November 10, 2026 – Adcendo ApS (“Adcendo”), a biotech company focused on...
Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
Combining a potential best-in-class tissue factor-targeting ADC with anti-PD-1 therapy may enhance the anti-tumor activity of the combination due to the complementary nature of the two mechanisms Adcendo will sponsor the Phase 1b clinical trial and MSD will provide...
Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
ADCE-T02, a potential best-in-class Tissue Factor targeted antibody-drug conjugate (ADC), enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors Two ADCE-T02 publications highlighting important preclinical results at the 2026 AACR Annual...
Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
Oversubscribed financing led by Jeito Capital, including additional new investment from Vida Ventures, BPI France, and EIFO, with participation from all existing investors Proceeds to support the advancement of three first- and best-in-class ADC programs through...
Adcendo ApS Announces FDA Fast Track Designation Granted to ADCE-D01 for the Treatment of Soft Tissue Sarcoma
ADCE-D01 is a first-in-class antibody-drug conjugate targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes Fast Track designation underscores the potential for ADCE-D01 to address the...
Adcendo ApS to Participate in Upcoming September Investor Conferences
COPENHAGEN, Denmark, Aug. 27, 2025 – Adcendo, a clinical-stage biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, today announced that management will participate in five upcoming investor...
Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01
ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes The ADCElerate1 trial will enroll patients in the US and Europe Copenhagen,...
Adcendo ApS to Present Data on its Clinical Stage ADCs ADCE-T02 and ADCE-D01 at the 2025 American Association for Cancer Research (AACR) Annual Meeting
ADCE-T02 - a potential first and best-in-class topoisomerase-1 (Topo-1) inhibitor-based Antibody-Drug Conjugate (ADC) against Tissue Factor - demonstrates strong and broad preclinical efficacy and good tolerability ADCE-D01 - a first-in-class ADC against urokinase...
Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team
Healthcare pioneer Laura Shawver, Ph.D. appointed Chair of the Board and industry veteran RoyBaynes M.D., Ph.D. appointed as independent, non-executive Director Fang Z. Ni, Pharm.D. named Chief Financial Officer Company expands global footprint by establishing U.S....